BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

820 related articles for article (PubMed ID: 18199717)

  • 1. Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression.
    Jin Z; Hamilton JP; Yang J; Mori Y; Olaru A; Sato F; Ito T; Kan T; Cheng Y; Paun B; David S; Beer DG; Agarwal R; Abraham JM; Meltzer SJ
    Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):111-7. PubMed ID: 18199717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypermethylation of the nel-like 1 gene is a common and early event and is associated with poor prognosis in early-stage esophageal adenocarcinoma.
    Jin Z; Mori Y; Yang J; Sato F; Ito T; Cheng Y; Paun B; Hamilton JP; Kan T; Olaru A; David S; Agarwal R; Abraham JM; Beer D; Montgomery E; Meltzer SJ
    Oncogene; 2007 Sep; 26(43):6332-40. PubMed ID: 17452981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypermethylation of tachykinin-1 is a potential biomarker in human esophageal cancer.
    Jin Z; Olaru A; Yang J; Sato F; Cheng Y; Kan T; Mori Y; Mantzur C; Paun B; Hamilton JP; Ito T; Wang S; David S; Agarwal R; Beer DG; Abraham JM; Meltzer SJ
    Clin Cancer Res; 2007 Nov; 13(21):6293-300. PubMed ID: 17975140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MAL hypermethylation is a tissue-specific event that correlates with MAL mRNA expression in esophageal carcinoma.
    Jin Z; Wang L; Zhang Y; Cheng Y; Gao Y; Feng X; Dong M; Cao Z; Chen S; Yu H; Zhao Z; Zhang X; Liu J; Mori Y; Fan X; Meltzer SJ
    Sci Rep; 2013 Oct; 3():2838. PubMed ID: 24088706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Temporal evolution in caveolin 1 methylation levels during human esophageal carcinogenesis.
    Jin Z; Wang L; Cao Z; Cheng Y; Gao Y; Feng X; Chen S; Yu H; Wu W; Zhao Z; Dong M; Zhang X; Liu J; Fan X; Mori Y; Meltzer SJ
    BMC Cancer; 2014 May; 14():345. PubMed ID: 24885118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promoter hypermethylation of CDH13 is a common, early event in human esophageal adenocarcinogenesis and correlates with clinical risk factors.
    Jin Z; Cheng Y; Olaru A; Kan T; Yang J; Paun B; Ito T; Hamilton JP; David S; Agarwal R; Selaru FM; Sato F; Abraham JM; Beer DG; Mori Y; Shimada Y; Meltzer SJ
    Int J Cancer; 2008 Nov; 123(10):2331-6. PubMed ID: 18729198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endoglin promoter hypermethylation identifies a field defect in human primary esophageal cancer.
    Jin Z; Zhao Z; Cheng Y; Dong M; Zhang X; Wang L; Fan X; Feng X; Mori Y; Meltzer SJ
    Cancer; 2013 Oct; 119(20):3604-9. PubMed ID: 23893879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus.
    Zou H; Molina JR; Harrington JJ; Osborn NK; Klatt KK; Romero Y; Burgart LJ; Ahlquist DA
    Int J Cancer; 2005 Sep; 116(4):584-91. PubMed ID: 15825175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk.
    Schulmann K; Sterian A; Berki A; Yin J; Sato F; Xu Y; Olaru A; Wang S; Mori Y; Deacu E; Hamilton J; Kan T; Krasna MJ; Beer DG; Pepe MS; Abraham JM; Feng Z; Schmiegel W; Greenwald BD; Meltzer SJ
    Oncogene; 2005 Jun; 24(25):4138-48. PubMed ID: 15824739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reprimo methylation is a potential biomarker of Barrett's-Associated esophageal neoplastic progression.
    Hamilton JP; Sato F; Jin Z; Greenwald BD; Ito T; Mori Y; Paun BC; Kan T; Cheng Y; Wang S; Yang J; Abraham JM; Meltzer SJ
    Clin Cancer Res; 2006 Nov; 12(22):6637-42. PubMed ID: 17121882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequent methylation of eyes absent 4 gene in Barrett's esophagus and esophageal adenocarcinoma.
    Zou H; Osborn NK; Harrington JJ; Klatt KK; Molina JR; Burgart LJ; Ahlquist DA
    Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):830-4. PubMed ID: 15824152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypermethylation of the somatostatin promoter is a common, early event in human esophageal carcinogenesis.
    Jin Z; Mori Y; Hamilton JP; Olaru A; Sato F; Yang J; Ito T; Kan T; Agarwal R; Meltzer SJ
    Cancer; 2008 Jan; 112(1):43-9. PubMed ID: 17999418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrantly methylated PKP1 in the progression of Barrett's esophagus to esophageal adenocarcinoma.
    Kaz AM; Luo Y; Dzieciatkowski S; Chak A; Willis JE; Upton MP; Leidner RS; Grady WM
    Genes Chromosomes Cancer; 2012 Apr; 51(4):384-93. PubMed ID: 22170739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma.
    Eads CA; Lord RV; Kurumboor SK; Wickramasinghe K; Skinner ML; Long TI; Peters JH; DeMeester TR; Danenberg KD; Danenberg PV; Laird PW; Skinner KA
    Cancer Res; 2000 Sep; 60(18):5021-6. PubMed ID: 11016622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Esophageal pepsin and proton pump synthesis in barrett's esophagus and esophageal adenocarcinoma.
    Samuels TL; Altman KW; Gould JC; Kindel T; Bosler M; MacKinnon A; Hagen CE; Johnston N
    Laryngoscope; 2019 Dec; 129(12):2687-2695. PubMed ID: 31046139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Subtypes of Barrett's Esophagus and Esophageal Adenocarcinoma Based on DNA Methylation Profiles and Integration of Transcriptome and Genome Data.
    Jammula S; Katz-Summercorn AC; Li X; Linossi C; Smyth E; Killcoyne S; Biasci D; Subash VV; Abbas S; Blasko A; Devonshire G; Grantham A; Wronowski F; O'Donovan M; Grehan N; Eldridge MD; Tavaré S; ; Fitzgerald RC
    Gastroenterology; 2020 May; 158(6):1682-1697.e1. PubMed ID: 32032585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypermethylation and loss of expression of glutathione peroxidase-3 in Barrett's tumorigenesis.
    Lee OJ; Schneider-Stock R; McChesney PA; Kuester D; Roessner A; Vieth M; Moskaluk CA; El-Rifai W
    Neoplasia; 2005 Sep; 7(9):854-61. PubMed ID: 16229808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of epigenetic alterations in the pathogenesis of Barrett's esophagus and esophageal adenocarcinoma.
    Agarwal A; Polineni R; Hussein Z; Vigoda I; Bhagat TD; Bhattacharyya S; Maitra A; Verma A
    Int J Clin Exp Pathol; 2012; 5(5):382-96. PubMed ID: 22808291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p16 expression in Barrett's esophagus and esophageal adenocarcinoma: association with genetic and epigenetic alterations.
    Hardie LJ; Darnton SJ; Wallis YL; Chauhan A; Hainaut P; Wild CP; Casson AG
    Cancer Lett; 2005 Jan; 217(2):221-30. PubMed ID: 15617840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disintegrin and metalloproteinases (ADAMs) expression in gastroesophageal reflux disease and in esophageal adenocarcinoma.
    Kauttu T; Mustonen H; Vainionpää S; Krogerus L; Ilonen I; Räsänen J; Salo J; Puolakkainen P
    Clin Transl Oncol; 2017 Jan; 19(1):58-66. PubMed ID: 27026568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.